DR. ROBERT A. ROSTOCK, M.D., FACRO

WILKES BARRE, PA

Research Active
Radiology - Radiation Oncology NPI registered 21+ years 5 publications 1985 – 2020 NPI: 1841292943
NeoplasmsCarcinoma, Squamous CellAntineoplastic AgentsSeverity of Illness IndexAdministration, OralRadiotherapy DosageDiarrheaAnti-Inflammatory Agents, Non-SteroidalDose-Response Relationship, DrugMorbidityRadiation InjuriesPlacebosMelenaPentosan Sulfuric PolyesterProctitis

Practice Location

1000 E MOUNTAIN BLVD
WILKES BARRE, PA 18711-0027

Phone: (570) 808-7075

What does ROBERT ROSTOCK research?

Dr. Rostock studies the effects of radiation therapy on various cancers and the ways to enhance treatment outcomes while minimizing side effects. His research includes examining treatments for gastrointestinal issues that arise after radiation therapy, as well as investigating the effectiveness of specific drugs in combination with radiotherapy for cancers such as head and neck cancer. Additionally, he has worked on developing new technologies that improve the delivery of heat therapy (hyperthermia) to cancerous tissues, aiming to make treatments safer and more effective for patients.

Key findings

  • Live tracking of tumor movement during stereotactic body radiation therapy (SBRT) showed serious side effects were ten times lower than traditional methods, significantly improving patient safety.
  • In a study involving 168 patients, pentosanpolysulfate (PPS) did not show a significant improvement in gastrointestinal issues after radiation, indicating it may not be an effective treatment for these patients.
  • In a trial with advanced head and neck cancer patients, 64% managed to control their cancer for a year and 59% for two years with concurrent tirapazamine and radiotherapy.
  • New microwave interstitial applicators for hyperthermia doubled the treatment volume compared to older designs, significantly improving the effectiveness of this cancer treatment.
  • Research on adenoid cystic carcinoma highlighted that despite radiation treatment, many patients experienced recurring cancer and poor outcomes.

Frequently asked questions

Does Dr. Rostock study gastrointestinal problems related to cancer treatment?
Yes, he researched the effectiveness of pentosanpolysulfate in treating gastrointestinal issues that can occur after radiation therapy.
What types of cancers does Dr. Rostock focus on?
Dr. Rostock studies various cancers, including advanced head and neck cancers and rare types such as adenoid cystic carcinoma.
What treatments has Dr. Rostock researched?
He has researched stereotactic body radiation therapy, hyperthermia, and the use of specific drugs like tirapazamine in conjunction with radiation.
Is Dr. Rostock's work relevant to patients receiving radiation therapy?
Absolutely, his research aims to improve the safety and effectiveness of radiation therapy, directly impacting cancer patients.
How does Dr. Rostock's research improve cancer treatment?
His findings help develop better treatment techniques and technologies that minimize side effects, improving patient outcomes.

Publications in plain English

Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response Models.

2020

Frontiers in oncology

Mahadevan A, Emami B, Grimm J, Kleinberg LR, Redmond KJ +13 more

Plain English
This study looked at how well different methods of handling tumor movement caused by breathing affect the side effects of a type of cancer treatment called stereotactic body radiation therapy (SBRT). They found that when doctors used live tracking of tumor movement, the chance of serious side effects (grade 3 or higher) was about ten times lower compared to other methods, especially for organs like the aorta and small bowel. This is important because it shows that better management of breathing motion can lead to safer treatment options for patients with moving tumors. Who this helps: This helps patients undergoing SBRT for tumors that shift with respiration.

PubMed

Phase III study of pentosanpolysulfate (PPS) in treatment of gastrointestinal tract sequelae of radiotherapy.

2006

American journal of clinical oncology

Pilepich MV, Paulus R, St Clair W, Brasacchio RA, Rostock R +1 more

Plain English
This study looked at whether a medication called pentosanpolysulfate (PPS) could help patients who experienced gastrointestinal problems after radiation therapy, such as proctitis, diarrhea, or bleeding. Researchers treated 168 patients with one of three options: 100 mg of PPS, 200 mg of PPS, or a placebo, but found no significant difference in symptom improvement or quality of life across any of the groups. This outcome is important because it suggests that PPS does not effectively alleviate the gastrointestinal side effects that some cancer survivors face after radiation. Who this helps: This information is relevant for patients who have suffered from radiation-related gastrointestinal issues and their healthcare providers.

PubMed

Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study.

1998

International journal of radiation oncology, biology, physics

Lee DJ, Trotti A, Spencer S, Rostock R, Fisher C +3 more

Plain English
This study looked at the effects of a drug called tirapazamine when used alongside radiation therapy in patients with advanced head and neck cancers. Out of 39 patients treated, 64% managed to control their cancer for a year, and 59% for two years. While some side effects were common, like muscle cramps and nausea, the overall treatment was well tolerated. Who this helps: This benefits patients with advanced head and neck cancers.

PubMed

A new design of microwave interstitial applicators for hyperthermia with improved treatment volume.

1986

International journal of radiation oncology, biology, physics

Lee DJ, O'Neill MJ, Lam KS, Rostock R, Lam WC

Plain English
Researchers developed new microwave applicators for a treatment called hyperthermia, which uses heat to kill cancer cells. These new applicators can treat twice the volume of tissue—improving treatment effectiveness by 100% compared to older designs. This matters because a larger treatment area means better chances of fighting tumors without harming surrounding healthy tissue. Who this helps: This benefits cancer patients undergoing hyperthermia treatment.

PubMed

Adenoid cystic carcinoma of the nasopharynx. Case reports and literature review.

1985

The Annals of otology, rhinology, and laryngology

Lee DJ, Smith RR, Spaziani JT, Rostock R, Holliday M +1 more

Plain English
This study looked at adenoid cystic carcinoma, a rare type of cancer in the nasopharynx, by sharing three new cases and reviewing previous reports. The researchers found that symptoms included facial pain, ear problems, and double vision, and while treatment with radiation helped relieve symptoms, two of the patients later had recurring cancer and spread of the disease. Overall, the findings highlight that despite aggressive treatment, patients often face poor outcomes. Who this helps: This information benefits doctors and patients by improving understanding of the disease's challenges and treatment effectiveness.

PubMed

Frequent Co-Authors

D J Lee Anand Mahadevan Bahman Emami Jimm Grimm Lawrence R Kleinberg Kristin J Redmond James S Welsh Eric Kemmerer Kenneth M Forster Jason Stanford

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.